Cue Biopharma, Inc.
CUE
$30.44
$1.364.68%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 21.94M | 2.15M | 2.95M | 421.00K | 1.58M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.94M | 2.15M | 2.95M | 421.00K | 1.58M |
| Cost of Revenue | 15.93M | 4.15M | 7.91M | 7.65M | 6.38M |
| Gross Profit | 6.01M | -2.01M | -4.96M | -7.23M | -4.81M |
| SG&A Expenses | 4.05M | 5.54M | 3.68M | 5.07M | 4.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.98M | 9.69M | 11.59M | 12.72M | 11.21M |
| Operating Income | 1.96M | -7.54M | -8.64M | -12.30M | -9.63M |
| Income Before Tax | 2.09M | -7.45M | -8.48M | -12.26M | -9.50M |
| Income Tax Expenses | 500.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.59M | -7.45M | -8.48M | -12.26M | -9.50M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.59M | -7.45M | -8.48M | -12.26M | -9.50M |
| EBIT | 1.96M | -7.54M | -8.64M | -12.30M | -9.63M |
| EBITDA | 2.64M | -7.46M | -8.54M | -12.20M | -9.53M |
| EPS Basic | 0.44 | -2.22 | -2.67 | -4.95 | -3.84 |
| Normalized Basic EPS | 0.36 | -1.38 | -1.67 | -3.10 | -2.40 |
| EPS Diluted | 0.43 | -2.22 | -2.67 | -4.95 | -3.84 |
| Normalized Diluted EPS | 0.35 | -1.38 | -1.67 | -3.10 | -2.40 |
| Average Basic Shares Outstanding | 3.60M | 3.36M | 3.18M | 2.48M | 2.47M |
| Average Diluted Shares Outstanding | 3.68M | 3.36M | 3.18M | 2.48M | 2.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |